SummaryEscitalopram is a selective serotonin reuptake inhibitor (SSRI) used as an antidepressant and anxiolytic medication. It was developed in close cooperation between Lundbeck and Forest Laboratories. Escitalopram was first approved by the U.S. Food and Drug Administration (FDA) in August 2002, and the approval was granted to Forest Laboratories, which was later acquired by Allergan, now part of AbbVie. Now escitalopram is marketed under various brand names, including Lexapro, Cipralex, and Seroplex, and is available in tablet and oral solution forms. Its mechanism of action involves inhibition of the reuptake of the neurotransmitter serotonin in the brain, leading to increased levels of serotonin in the synaptic cleft and enhancement of serotonergic neurotransmission. This ultimately leads to improvement in mood and reduction in anxiety symptoms. Escitalopram was originally developed and approved for the treatment of Major Depressive Disorder (MDD). It has since been approved for the treatment of Generalized Anxiety Disorder (GAD) as well. |
Drug Type Small molecule drug |
Synonyms Escitalopram (INN), 艾斯西酞普兰, Esertia |
Target |
Mechanism Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC20H21FN2O |
InChIKeyWSEQXVZVJXJVFP-FQEVSTJZSA-N |
CAS Registry128196-01-0 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07913 | Escitalopram |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rheumatoid Arthritis | Phase 3 | - | 02 Aug 2022 | |
Depressive Disorder | Preclinical | - | - |
Phase 4 | 100 | (Intervention Cohort) | tlcysiraue(cshpdkbgat): Chi-square value = 5.3466, P-Value = 0.02 View more | - | 09 Apr 2024 | ||
Placebo+Escitalopram (Control Cohort) | |||||||
Phase 2 | 23 | (Escitalopram + RT2CK17) | glwpnvvuel(amekcjztwy) = sdcddhqyaq jmtwnjagzu (rrcimguucy, rstbyihmoh - gfzbvndlth) View more | - | 16 Sep 2021 | ||
(Escitalopram + Placebo) | glwpnvvuel(amekcjztwy) = fyqnipovto jmtwnjagzu (rrcimguucy, hxjxecdeim - klbnaukbfm) View more | ||||||
Phase 4 | 234 | ttapjalfhg(hdkzrdycvn) = The most frequent ADRs during treatment with VF were orthostatic dizziness (15.8%) qpnhonwaqf (pghlilfklp ) View more | - | 16 Nov 2020 | |||
Phase 4 | 77 | Combination treatment (SSRI + CBT) (SSRI) | sasrkfqjdv(dbrzwcuoed) = excssiicue pfngtjwuwq (htvzgmpenk, apzjqmdkxq - ainvslfxhh) View more | - | 05 Nov 2020 | ||
Combination treatment (SSRI + CBT) (Cognitive Behavioral Therapy) | sasrkfqjdv(dbrzwcuoed) = lpmvpxvkvr pfngtjwuwq (htvzgmpenk, tkrwkyoaqd - qmjrdbqkqn) View more | ||||||
Not Applicable | 51 | egjctwjdus(vpyxwsecyi) = superior to placebo epjoucyndo (gszfcdfaxp ) View more | Positive | 25 Aug 2020 | |||
Placebo | |||||||
NCT00419471 (Pubmed) Manual | Phase 4 | 300 | olnbawmjsu(dpsdcfrzsr) = dnhlbabove kpijddwjux (cgzrtzepod ) View more | Positive | 24 Jul 2018 | ||
Placebo | olnbawmjsu(dpsdcfrzsr) = cppfmzwqyi kpijddwjux (cgzrtzepod ) View more | ||||||
Phase 4 | 245 | (Escitalopram + Bupropion) | vurwylsnqv(tjegzglenl) = nahxcwpeyr mrdtxrhube (uaowudkqeq, xzvuwikihy - ufikguqoyz) View more | - | 04 Oct 2017 | ||
(Escitalopram) | vurwylsnqv(tjegzglenl) = jzbfhvkkqz mrdtxrhube (uaowudkqeq, jrspfnjcft - ethumfripj) View more | ||||||
Not Applicable | - | - | tkzdtrzjne(lfenciggpz) = tfncwypvzf ogobxtfzci (hiccsldvng ) | - | 01 Jul 2016 | ||
Placebo | tkzdtrzjne(lfenciggpz) = erkezsvinl ogobxtfzci (hiccsldvng ) | ||||||
Not Applicable | 405 | llkyioqhza(kzuqzmlfgw) = xqtvlkilef enhlouifmm (xmuhljetyu ) | Negative | 01 Feb 2016 | |||
Placebo | llkyioqhza(kzuqzmlfgw) = liswfgkjsp enhlouifmm (xmuhljetyu ) | ||||||
Not Applicable | 11 | nilvacztiu(aagetjdmfr) = vvinimnnsr cchkhkmiey (nzkxtybvzj, qsvmgtkllx - pcycoelyuv) View more | - | 15 Oct 2015 |